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A method using Liquid Phase Microextraction for simultaneous detection of citalopram (CIT), paroxetine (PAR) and fluoxetine 
(FLU), using venlafaxine as internal standard, in plasma by high performance liquid chromatography with fluorescence detection 
was developed. The linearity was evaluated between 5.0 and 500 ng mL-1 (r > 0.99) and the limit of quantification was 2.0, 3.0 and 
5.0 ng mL-1 for CIT, PAR and FLU, respectively. Therefore, it can be applied to therapeutic drug monitoring, pharmacokinetics or 
bioavailability studies and its advantages are that it necessary relatively inexpensive equipment and sample preparation techniques. 
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INTRODUCTION
Depression is a disorder that affects the part of the brain respon-
sible for mood regulation, and antidepressants are used to treat this 
disorder and elevate a patient’s mood.1 Controlling the efficacy of 
depression medication has been the subject of investigation after the 
discovery of the antidepressant properties of monoamine oxidase 
inhibitors (MAOIs), tricyclic antidepressants (TCA) and selective 
serotonin reuptake inhibitors (SSRI). These discoveries have led to 
progress in the treatment and understanding of possible mechanisms 
underlying depressive disorders.2 MAOIs and TCAs, although very 
effective, have undesirable side effects caused by the lack of speci-
ficity of their pharmacological action, and they are potentially lethal 
in cases of overdose.1,2
The SSRIs, citalopram (CIT), fluoxetine (FLU), fluvoxamine, 
paroxetine (PAR) and sertraline, are the result of research to find 
drugs as effective as TCAs, but with fewer problems with tolera-
bility and safety. SSRIs inhibit serotonin reuptake potently and 
selectively, resulting in the increase of serotonergic neurotransmis-
sion. Although they share the primary mechanism of action with 
TCAs, SSRIs are structurally distinct, with marked differences in 
the pharmacokinetic and pharmacodynamic profile. Sertraline and 
paroxetine are the most potent reuptake inhibitors. The relative 
potency of sertraline in inhibiting dopamine uptake differentiates it 
pharmacologically from other SSRIs. Citalopram and fluoxetine are 
racemic mixtures of chiral forms that have different pharmacokinetic 
and pharmacodynamic profiles. The fluoxetine metabolite is long 
acting and is pharmacologically active. SSRIs also have different 
pharmacokinetic profiles, including half-life, linear pharmacoki-
netics versus the non-linear effect of age on its clearance, and its 
potential to inhibit the drug-metabolising isoenzyme, cytochrome 
P450 (CYP). These differences underscore that the pharmacological 
and pharmacokinetic clinical differences have become increasingly 
important for SSRIs.2 Figure 1 shows the chemical structures of 
the SSRIs studied.
Several methods have been proposed for the detection of antide-
pressants in biological fluids for therapeutic monitoring, bioavaila-
bility studies and toxicological purposes, but the sample preparation 
is a critical step for isolating the target analytes. The choice of a par-
ticular sample preparation process is based on the physico-chemical 
constituents of the sample (analytes, interferences and matrices) such 
as polarity, solubility and chemical and thermal stability. It is also 
important to know or estimate the concentration of the analytes and 
potential interferences, the characteristics of the equipment available 
and the existence of an official methodology and the availability of 
skilled personnel.3
The techniques most commonly employed in the extraction and-
/-or pre-concentration of these drugs in biological fluids are protein 
precipitation, liquid-liquid extraction (LLE)4-6 and solid phase ex-
traction (SPE)7,8 prior the chromatographic analysis. Non-exhaustive 
techniques based on the principles of balance, pre-equilibrium and 
permeation can also be used. The non-exhaustive techniques are 
fundamentally similar to the exhaustive techniques; however, the 
Figure 1. Chemical structures of the antidepressants: fluoxetine, citalopram 
and paroxetine
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capacity of the extraction phase is small and, in most cases, is not 
sufficient to remove most of the analytes present in the matrix.3
The determination of SSRIs is possible using high performance 
liquid chromatography (HPLC) with ultra-violet (UV) and fluores-
cence (FL) or gas chromatography (GC) with nitrogen-phosphorus 
detectors (NPD).9 The simultaneous determination of CIT, PAR and 
FLU in plasma and blood samples by solid phase extraction (SPE) 
and HPLC-UV/FL has been studied,10 while a method using SPE and 
HPLC-MS was previously used for the determination of FLU, CIT, 
PAR and VEN in plasma samples.8
Liquid-liquid microextraction (Liquid Phase Microextraction, 
LPME) has gained attention in recent years, mainly as a technique 
for sample preparation for chromatographic and electrophoretic 
analysis of xenobiotics. Hollow fibre liquid-phase microextraction 
(HF-LPME) is a relatively new technique for sample preparation, 
introduced in 1999 which produces pre-concentrated analytes and 
provides an efficient “clean-up” effect.11 In this technique, the prin-
ciples of LLE are miniaturised, and the analytes are extracted from 
small volumes of biological material through an organic solvent 
immobilised in the pores of a hollow polypropylene fibre. Then the 
analytes migrate to a small volume of acceptor phase that is placed 
inside fibre.12,13 Recently, a method using a three-phase LPME coupled 
to an HPLC-fluorescence detector to analyse fluoxetine and its ac-
tive metabolite, norfluoxetine, in plasma samples was published.14 
However, it is important to develop methods that are able to detect 
multiple compounds for application in toxicological and forensic 
analysis, as a screening method for drug abuse cases. Therefore, 
the aim of this study was to develop a method to detect fluoxetine, 
citalopram and paroxetine in plasma samples using LPME coupled 
to liquid chromatographic analysis. 
EXPERIMENTAL
Chemicals 
HPLC-grade acetonitrile was purchased from Vetec (Rio de 
Janeiro, Brazil). HPLC-grade methanol and ethanol were obtained 
from J.T. Baker (Philipsburg, USA). Analytical-grade solvents were 
utilised, including n-octanol and n-hexyl ether from Sigma–Aldrich 
(St. Louis, USA), n-hexane from Mallinckrodt (Paris, USA), and 
toluene from Vetec (Rio de Janeiro, Brazil). Other chemicals that were 
used include the following: sodium acetate from Proquimios (Rio de 
Janeiro, Brazil), acetic acid and sodium chloride from Impex (Con-
tagem, Brazil), ammonium acetate from Ecibra (São Paulo, Brazil), 
sodium dihydrogen phosphate from Dinâmica (Diadema, Brazil), 
sodium hydroxide from Labsynth (Diadema, Brazil), hydrochloric 
acid from Vetec (Rio de Janeiro, Brazil) and perchloric acid from 
Reagen (Rio de Janeiro, Brazil). All aqueous solutions were prepared 
with purified water, which was obtained using a Milli-Q apparatus 
(Millipore Corporation, Bedford, USA). 
Standard and stock solutions
Citalopram (CIT) and fluoxetine (FLU), purity > 98%, were 
purchased from Sigma- Aldrich® (St. Louis, USA). Paroxetine (PAR) 
and venlafaxine (VEN) (internal standard) were purchased from 
Wyeth® (Madison, EUA). Standard stock solutions of antidepressants 
were prepared by dissolving 100 mg (± 0.1 mg) of each compound 
in 100 mL of methanol. The solutions were stored at -20 ºC between 
experiments. Standard working solutions were prepared daily by 
diluting the standard stock solution to concentrations of 0.5, 1.5, 5, 
10, 25 and 50 ng mL-1 and VEN to 50 ng mL-1.
HPLC conditions
Sample analyses were performed on a Shimadzu model LC-10AV 
(Kyoto, Japan) HPLC that was equipped with a LC-10AD pump, a 
CTO-10AS VP column oven, a SIL-10 AF automatic injector (50 mL 
loop), a SPD-10AVP UV detector and a RF-10AXL fluorescence 
detector. The chromatographic conditions established included a Li-
Chrospher 60 RP-Select B reverse-phase column (125 x 4 mm, 5 mm 
particle size) from Merck (Darmstadt, Germany), operating at 25 ºC. 
The mobile phase consisted of a 0.005 mol L-1 sodium acetate buffer 
(pH 4.5) and acetonitrile in a 50:50 (v/v) mixture at a 0.6 mL min -1 
flow rate. The fluorescence detector was set at 230 nm (excitation) 
and 290 nm (emission) for CIT and FLU, at 294 nm (excitation) and 
330 nm (emission) for PAR.
Sampling 
Drug-free human plasma samples used for LPME optimization 
and method validation were provided by healthy volunteers. Real 
plasma samples were collected from 3 patients undergoing treatment 
with CIT at doses varying between 10 and 20 mg day−1, 3 patients 
undergoing treatment with FLU at doses varying between 20 and 40 
mg day−1 and 2 patients undergoing treatment with PAR at doses of 
20 mg day−1. Blood samples from these volunteers were collected 
immediately prior to the drug administration (minimum plasma 
concentration). All of the patients signed a written and informed 
consent form prior to the investigation and the study was approved 
by the Ethics Committee of the Federal University of Alfenas (pro-
tocol number 23087.001196/2008-16). All of the blood samples 
were collected in Vacutainer heparinised tubes (Becton Dickinson, 
Meylan, France). These were subsequently centrifuged for 15 min 
at 560 x g, and the plasma samples were stored at -20 ºC for no 
longer than 2 weeks. 
Sample preparation
The LPME system consisted of a plasma solution (donor), ex-
tracting solvent and acceptor solution. A 1 mL sample (with 10 mL 
of a 50 ng mL-1 of a VEN solution) was placed in a conventional 5 
mL vial (Supelco, Bellefonte, USA), and its pH was adjusted using 
100 µL of a 5 mol L-1 sodium hydroxide solution. The sample was 
diluted with ultrapure water to a total volume of 5.0 mL. All of the 
LPME experiments were performed using Accurel Q3/2 polypropyl-
ene hollow fibre membranes (600 µm I.D., 200 µm wall thickness 
and 0.2 µm pore size) from Membrana (Wuppertal, Germany). These 
membranes were in a “U” format, as described previously.12,14 The 
hollow fibre was manually cut to 7 cm and then employed for LPME. 
Syringes (25 and 50 mL) with 22 s gauge bevelled tip needles (Ham-
ilton, Reno, USA) were used to connect the hollow fibre ends. One 
syringe served to introduce the acceptor solution, while another was 
used for collecting the final extract. Prior to extraction, the extract-
ing solvent was immobilised in the pores of the hollow fibre. This 
immobilisation was performed by dipping the fibre into n-hexyl 
ether for 10 s, followed by immersion in an ultrasonic water bath for 
15 s to remove excess solvent. Subsequently, 20 mL of the acceptor 
solution was injected into the hollow fibre and the assembly was im-
mersed into the sample directly. During extraction, the samples were 
stirred using 1 cm magnetic bars (Sigma–Aldrich, St. Louis, USA). 
After extraction, 20 mL of the acceptor solution was retracted into 
a 50 mL microsyringe and diluted to 100 mL with the mobile phase. 
An aliquot of 50 mL was injected into the chromatographic system. 
Three samples were processed simultaneously.
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Confidence parameters
The method was validated in-house using the following perfor-
mance criteria: selectivity, linearity and linear range, sensitivity, limit 
of quantification, intra-assay and inter-assay precision and accuracy, 
and extraction efficiency.
Selectivity of the method was evaluated by analysing blank and 
spiked plasma samples that were obtained from six individuals, four 
normal samples, one haemolysed and another lipaemic. The chroma-
tographic behaviour of other drugs that were added to the plasma and 
submitted to the method (i.e., diazepam, nordiazepam, amitriptyline, 
clomipramine, clonazepam, chlordiazepoxide, chlorpromazine, fena-
cetine, lorazepam, caffeine and nicotine) was also verified. 
The linearity, linear range and sensitivity were established throu-
gh the analytical curve obtained by 6 replicates per concentration, 
at 6 concentration levels between the limit of quantification (LOQ) 
and 500 ng mL-1. The sensitivity is the slope of the analytical curve. 
The LOQ was determined at a signal-to-noise ratio of 10 (S/N= 10). 
The intra-assay precision (repeatability) of the method, expressed 
as the relative standard deviation of the peak area measurements 
(n = 6), was evaluated through the results obtained by the method 
operating over one day, under the same conditions, using solutions 
of each analyte at three concentration levels, 5, 50 and 250 ng mL–1 
(50 ng mL–1 of VEN). The inter-assay precision was determined for 
the same 3 concentration levels, three replicates, and the analyses 
were performed for 3 days. 
Accuracy was established by spiking the plasma samples with 
15, 50 and 250 ng mL−1 (n = 3 per concentration). After LPME 
extraction and chromatographic analysis, results were compared to 
the theoretically added values. Recovery (extraction efficiency) was 
calculated from the plasma samples spiked with 15, 50 and 250 ng 
mL-1 (n = 3/each concentration). These recoveries were submitted for 
analysis by the studied method (LPME/HPLC-FL) and the results 
were compared with those obtained by direct acceptor phase addition 
of the same analyte quantities. 
RESULTS AND DISCUSSION
The methods of antidepressants analysis in plasma must present 
high detectability to allow detection of low quantities of analytes (ng 
mL-1). The HPLC with FL detection employing LPME can be used in 
routine analysis of these drugs since it is a simple, inexpensive and 
reliable alternative to others sample preparation techniques.
Chromatographic conditions 
The retention times obtained in the chromatographic conditions 
established were 7.52 min (VEN), 10.32 min (CIT), 14.81 min (PAR) 
and 17.15 min (FLU). System suitability parameters of the chroma-
tographic analysis (Table 1), including adequate efficiency (number 
of plates, N, above 2000), resolution (Rs ≥ 2), tailing factor (TF ≤ 
2) and capacity factor (k’ > 2), were adequate according to US-FDA 
recommendations.15,16 Figure 2 shows the chromatograms of the drugs 
extracted from plasma by LPME using the optimised chromatographic 
conditions established for this analysis. These conditions, in addition 
to increasing the method sensitivity, result in better method selectivi-
ty. Fluorescence spectroscopy was used as a sensitive and selective 
detection method for compounds that fluoresce.17 In this study, this 
detector increased the peak sensitivity. 
LPME conditions 
In this study, LPME was optimised for citalopram, fluoxetine 
and paroxetine using the parameters evaluated in a previous study.14 
The three-phase system can ionise acidic and basic analytes. The pka 
value of CIT, PAR and FLU is 9.6, 10.3 and 10.05, respectively,18 
and the pH of plasma sample solutions is known to play an essential 
role in the extraction of these drugs. They should be in their neutral 
form, making them extractable by the organic solvent immobilised 
in the fibre pore. The acceptor phase for trapping the analyte should 
be acidic to guarantee prevalence of the ionised form. This form does 
not diffuse back into the organic solvent.14
Table 1. System suitability parameters to developed method to simultaneous analysis of antidepressants in plasma samples
Drugsa Retention time Number of plates (N) Resolutionb (Rs) Tailing factor (TF) Capacity factor (k’) 
VEN 7.52 2535.20 - 1.30 6.51
CIT 10.32 3946.87 4.31 1.23 9.20
PAR 11.81 4547.11 2.61 1.19 10.85
FLU 17.15 6209.66 6.57 1.15 15.98
aVenfalaxine (VEN); citalopram (CIT), paroxetine (PAR) and fluoxetine (FLU); bResolution was calculated between: citalopram and venlafaxine; paroxetine 
and citalopram; fluoxetine and paroxetine. 
Figure 2. Characteristic chromatograms: (A) blank sample; (B) patient treated 
with 20 mg day-1 citalopram; (C) patient treated with 20 mg day-1 paroxetine; 
(D) patient treated with 20 mg day-1 fluoxetine
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inter-assay precision was assessed at three concentration levels, and 
the results are shown in Table 3. 
All values of the relative standard deviations were below 10% 
and are, therefore, acceptable for the analyses of biological samples. 
Accuracy was evaluated by comparing the theoretical concentrations 
to the obtained concentrations. Samples containing the citalopram, 
fluoxetine and paroxetine were analysed in three replicates (Table 4). 
The LPME is a non- exhaustive technique, meaning that the analyte 
is transferred gradually to the acceptor solution until its concentration 
is constant. 22,32,33 Low recovery in LPME, compared to LLE extrac-
tion, is a common problem due to the micro-scale characteristic of 
the technique.24 Furthermore, it should be taken into account that the 
extraction procedure results in high enrichment values. This method 
also enables a direct injection of the total amount of the acceptor 
phase material.22
Application of the method
The proposed method was applied to analyse plasma samples 
from human patients treated with CIT, PAR and FLU. Plasma con-
In general, the chosen organic solvent must be immiscible with 
the acceptor and donor phase (sample), must be compatible with the 
membrane, must be of low volatility and must present affinity for 
the analyte to be tested.19-22 According to the results, n-hexyl ether 
resulted in satisfactory extraction efficiency. The pH adjustment of 
the plasma sample is an essential step in this system to guarantee 
the highest extraction coefficient and to increase the efficiency.20 
A pH value of 14, adjusted by 2 mol L-1 NaOH, resulted in the 
highest efficiency.
In LPME, sufficient time is needed to permit partitioning of 
the analyte between the two liquid phases because it is an equilib-
rium system. An exposure time of 40 min was selected because it 
provides a satisfactory efficiency and can be applied in laboratory 
routine. Magnetic bars can cause cross contamination of samples and 
can lead the formation of air bubbles that may adhere on the fibre 
surface, accelerating the evaporation of the solvent.23 This problem 
was avoided by maintaining a moderate and constant agitation rate 
for all samples during the procedure. The extraction kinetics can 
be accelerated by shaking the sample, which facilitates the diffu-
sion of the analytes from the donor phase through the extraction 
solution to the acceptor solution.24 The stirring speed of 1400 rpm 
was selected because a higher velocity introduced more inaccuracy 
in the analyses.
When using the three-phase LPME system for the extraction of 
basic drugs, the pH of the acceptor solution should be in the acidic 
range, thus ensuring the protonation of the analytes and avoiding 
losses of the same solution for the donor.13,25 Among the acids studied, 
a 20 mmol L-1 HCl solution of pH 2.0 showed the greatest recovery 
of the analytes. This acid is the most quoted in literature for use as 
the acceptor solution.13,26-29 
The drug-protein interactions are usually responsible for the low 
recovery values. Because of this interaction, it is common to add 
an organic solvent in the donor solution (sample) to suppress the 
drug-protein bonds.13 Methanol gave the best response increasing 
the peak area around 16.6 times. This alcohol has the ability to dis-
rupt hydrophobic and polar interactions between the analyte and the 
proteins.12,30,31 However, the addition of methanol interfered with the 
accuracy of the method, reducing the repeatability of the extraction.
The optimum LPME conditions established for CIT, PAR and 
FLX extraction from plasma samples, based on the results discussed 
previously, are the following: n-hexyl ether as the organic solvent; 
addition of a 1 mL plasma sample with 100 µL of 2 mol L-1 NaOH, 
with subsequent dilution to 5 mL with purified water; 40 min extrac-
tion time with a stirring speed of 1400 rpm; and 20 µL of 20 mmol 
L-1 HCl as the acceptor phase. The selectivity of the LPME technique 
and of the method developed is shown in Figure 2A: a blank sample 
was analysed and no interfering peaks from endogenous compounds 
were observed in the chromatogram. Blank matrices added to the 
other drugs were also tested and none of these drugs presented any 
response in the fluorescence detector used.
Confidence parameters
The method was validated for the determination of CIT, PAR 
and FLU in plasma samples, using VEN as an internal standard. 
The linearity, linear range, sensitivity and limit of quantification 
were obtained by calibration (Table 2). The linearity was tested 
using a pure error lack of fit test with a simple regression, which 
was not significant at the 5% level. The limit of quantification of 
the method was 2.0, 3.0 and 5.0 ng mL-1 for CIT, PAR and FLU, 
respectively. The linear range of concentrations for this method 
can be satisfactorily applied to therapeutic drug monitoring, phar-
macokinetics or biodisponibility studies of these drugs. Intra- and 
Table 2. Validation parameters obtained from the calibration in plasma samples 
by the method developed
Drug Linear 
range (ng mL-1)
Sensitivity Intercept Linearity (r)
Citalopram 2.0- 500 0.0072 0.0103 0.9992
Fluoxetine 5.0-500 0.003 0.007 0.9975
Paroxetine 3.0- 500 0.006 0.054 0.9985
Table 3. Intra- and inter-assay precision, evaluated by the relative standard 
deviation, for the determination of citalopram (CIT), fluoxetine (FLU) and 
paroxetine (PAR) in plasma samples by the method developed
aRSD (%)
Drug 5 ng mL-1 50 ng mL-1 250 ng mL-1
CIT
Intra-assay precision 
Inter-assay precision
6.8
2.0
8.2
4.5
6.7
5.7
FLU
Intra-assay precision 
Inter-assay precision
3.6
6.6
5.5
4.8
2.9
4.9
PAR
Intra-assay precision 
Inter-assay precision
5.8
3.5
6.3
4.0
6.6
5.2
aRSD: relative standard deviation
Table 4. Accuracy and extraction efficiency for the determination of citalo-
pram (CIT), fluoxetine (FLU) and paroxetine (PAR) in plasma samples by 
the method developed 
Drug 15 ng mL-1 50 ng mL-1 250 ng mL-1
CIT
Accuracy (%)
Extraction efficiency (%)
94.2
75.9
88.5
78.4
99.8
78.5
FLU
Accuracy (%)
Extraction efficiency (%)
99.6
67.0
90.3
64.9
88.7
66.1
PAR
Accuracy (%)
Extraction efficiency (%)
100.3
67.5
88.9
71.3
90.3
70.7
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centrations of citalopram are proportional to the doses administered 
with linear pharmacokinetics. This drug class, compared to other 
SSRIs, shows less binding to plasma proteins. The therapeutic range 
found in the literature is 40 to 200 ng mL-1.2,10 Figure 2B shows the 
chromatogram of the analysis of one patient. It is interesting to note 
that this patient started treatment with citalopram about 1 week 
before blood collection and had previously used paroxetine. Thus, 
it was possible to identify traces of paroxetine in the plasma (3.57 
ng mL-1), demonstrating the satisfactory sensitivity of the method 
and its breadth in the detection of both drugs simultaneously. Table 
5 shows the values of PAR in the plasma of two patients undergoing 
treatment with this drug, and Figure 2C shows a characteristic 
chromatogram. The therapeutic range for PAR in plasma is 20 to 
190 ng mL-1.2,10 The plasma levels of fluoxetine in three patients 
are shown in Table 5, and a chromatogram of one of these patients 
is shown in Figure 2D. The FLU has nonlinear pharmacokinetics; 
the plasmatic concentration dose is not proportional to that dose.34 
The optimal therapeutic range for FLU is not established with 
certainty, although plasmatic concentrations correlate better with 
the patient’s clinical response. Values between 50 and 500 ng mL-1 
are cited as the optimal therapeutic range, considering the different 
dosages of the drug.35
CONCLUSIONS 
A suitable LPME extraction followed by HPLC-FL method 
was developed and validated for the simultaneous determination of 
citalopram, fluoxetine, paroxetine and venlafaxine (internal standard, 
I.S.) in human plasma. This method provides a good alternative to 
existing methods for analyzing antidepressants employing LPME. 
The major advantage of this method over similar methods is that it 
is performed in isocratic mode and it is free from endogenous com-
pounds. In addition, it is necessary relatively inexpensive equipment 
and sample preparation techniques, which are usually employed in 
routine analyses of drugs in biological specimens. Its wide linear 
range, precision and accuracy allow application to biomedical and 
toxicological analysis of these drugs in plasma.
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Table 5. Citalopram, fluoxetine and paroxetine in plasma samples from pa-
tients treated with the drugs analysed by the proposed method
Sample Concentration (ng mL-1) Dose (mg day-1)
Citalopram
C1 67.91 20
C2 91.61 20
C3 52.66 10
Fluoxetine
F1 116.14 20
F2 79.87 20
F3 187.98 40
Paroxetine
P1 41.31 20
P2 71.17 20
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